Bio-Med
Bio-Med (P) Limited is dedicated to producing world-class vaccines essential for a developing country like India. With state-of-the-art facilities and a focus on quality, research, and innovation, Bio-Med has earned recognition both nationally and internationally. The company emphasizes prevention over cure and aims to control and prevent infectious diseases through its range of vaccines and healthcare products.
Industries
Nr. of Employees
small (1-50)
Products
Bio Typh (Typhoid polysaccharide vaccine)
Vi capsular polysaccharide vaccine for prevention of typhoid fever; each 0.5 ml dose contains 25 mcg Vi antigen and phenol preservative as per pharmacopeial specifications.
Vi conjugate typhoid vaccine (Vi–protein conjugate)
Polysaccharide (Vi) conjugated to a carrier protein for improved immunogenicity in infants and young children; evaluated in open multicentre clinical trials with ELISA-based immunogenicity endpoints.
Avian infectious bronchitis vaccine (live attenuated, freeze-dried)
Live attenuated avian infectious bronchitis vaccine presented in freeze-dried form; contains defined EID50 titre of Massachusetts strain per dose and is reconstituted prior to administration (drinking water or other routes).
Haemorrhagic septicaemia and black quarter vaccine (inactivated, adjuvanted)
Formalin-inactivated bacterial vaccine containing Pasteurella multocida and Clostridium chauvoei bacterins adjuvanted with aluminium hydroxide gel for cattle; supplied in multi-dose vials with recommended booster schedules.
Ethyl alcohol based hand sanitizer (WHO formulation)
Instant hand rub formulation following WHO-recommended composition: 80% v/v ethyl alcohol with glycerol and hydrogen peroxide; supplied in multiple pack sizes.
Bio Typh (Typhoid polysaccharide vaccine)
Vi capsular polysaccharide vaccine for prevention of typhoid fever; each 0.5 ml dose contains 25 mcg Vi antigen and phenol preservative as per pharmacopeial specifications.
Vi conjugate typhoid vaccine (Vi–protein conjugate)
Polysaccharide (Vi) conjugated to a carrier protein for improved immunogenicity in infants and young children; evaluated in open multicentre clinical trials with ELISA-based immunogenicity endpoints.
Avian infectious bronchitis vaccine (live attenuated, freeze-dried)
Live attenuated avian infectious bronchitis vaccine presented in freeze-dried form; contains defined EID50 titre of Massachusetts strain per dose and is reconstituted prior to administration (drinking water or other routes).
Haemorrhagic septicaemia and black quarter vaccine (inactivated, adjuvanted)
Formalin-inactivated bacterial vaccine containing Pasteurella multocida and Clostridium chauvoei bacterins adjuvanted with aluminium hydroxide gel for cattle; supplied in multi-dose vials with recommended booster schedules.
Ethyl alcohol based hand sanitizer (WHO formulation)
Instant hand rub formulation following WHO-recommended composition: 80% v/v ethyl alcohol with glycerol and hydrogen peroxide; supplied in multiple pack sizes.
Services
Design and execution of open, multicentre controlled clinical trials including site coordination, ethics approvals and safety/immunogenicity assessment.
System for monitoring local and systemic adverse events and conducting post-licensure follow-up studies for vaccine safety and immunogenicity.
Accredited R&D laboratories providing assay development and validation (including ELISA calibration against reference standards).
Quality management activities to ensure products conform to pharmacopeial and international quality standards and to support regulatory submissions and approvals.
Formulation of inactivated and live attenuated vaccines, adjuvanting, vial filling in single- and multi-dose formats and guidance on storage/administration.
Design and execution of open, multicentre controlled clinical trials including site coordination, ethics approvals and safety/immunogenicity assessment.
System for monitoring local and systemic adverse events and conducting post-licensure follow-up studies for vaccine safety and immunogenicity.
Accredited R&D laboratories providing assay development and validation (including ELISA calibration against reference standards).
Quality management activities to ensure products conform to pharmacopeial and international quality standards and to support regulatory submissions and approvals.
Formulation of inactivated and live attenuated vaccines, adjuvanting, vial filling in single- and multi-dose formats and guidance on storage/administration.
Expertise Areas
- Vaccine research and development
- Conjugate vaccine development
- Clinical trial management (multicentric trials)
- Immunoassay development and validation (ELISA)
Key Technologies
- Polysaccharide-protein conjugation (conjugate vaccines)
- Polysaccharide vaccine manufacturing
- Lyophilization / freeze-drying
- Aluminium hydroxide adjuvant formulations
News & Updates
Clinical Trial of Vi Conjugate Typhoid Vaccine (Peda Typh™)
A detailed report on the clinical trial conducted in India demonstrating the safety and immunogenicity of Peda Typh™ in infants and children.
Efficacy and Safety Studies of Peda Typh™
Studies showing 100% efficacy in preventing typhoid in a one-year follow-up and safety in all age groups.
Clinical Trial of Tetanus Toxoid Conjugated Vi Polysaccharide Typhoid Vaccine in Infants and Young Children
Published in Biotechnology International, 2014, this article discusses the safety, immunogenicity, and efficacy of Peda Typh™.
Safety and Immunogenicity of Salmonella typhi Vi Conjugate Vaccine (Peda Typh™) in Children Upto Five Years
Published in the International Journal of Scientific and Research Publication, 2013, this study confirms the safety and immune response in children.
Efficacy and Safety of Vi-Tetanus Toxoid Conjugated Typhoid Vaccine (Peda Typh™) in Indian Children
A school-based cluster randomized study published in Human Vaccine & Immunotherapeutics, 2016, showing 100% efficacy over one year.
Development of Indigenous Typhoid Vaccines
Bio-Med developed and launched the first indigenously manufactured Vi antigen typhoid vaccine in India, contributing to the 'Make in India' initiative.
Clinical Trial of Vi Conjugate Typhoid Vaccine (Peda Typh™)
A detailed report on the clinical trial conducted in India demonstrating the safety and immunogenicity of Peda Typh™ in infants and children.
Efficacy and Safety Studies of Peda Typh™
Studies showing 100% efficacy in preventing typhoid in a one-year follow-up and safety in all age groups.
Clinical Trial of Tetanus Toxoid Conjugated Vi Polysaccharide Typhoid Vaccine in Infants and Young Children
Published in Biotechnology International, 2014, this article discusses the safety, immunogenicity, and efficacy of Peda Typh™.
Safety and Immunogenicity of Salmonella typhi Vi Conjugate Vaccine (Peda Typh™) in Children Upto Five Years
Published in the International Journal of Scientific and Research Publication, 2013, this study confirms the safety and immune response in children.
Efficacy and Safety of Vi-Tetanus Toxoid Conjugated Typhoid Vaccine (Peda Typh™) in Indian Children
A school-based cluster randomized study published in Human Vaccine & Immunotherapeutics, 2016, showing 100% efficacy over one year.
Development of Indigenous Typhoid Vaccines
Bio-Med developed and launched the first indigenously manufactured Vi antigen typhoid vaccine in India, contributing to the 'Make in India' initiative.